Intraocular lens (IOL) - hydrophilic acrylic - opacification
(intraocular lens (IOL) - hydrophilic acrylic) opacification of intraocular lens (IOLs) may occur following intracameral use of alteplase. (MDA/2010/008)
Device
Intraocular lens (IOL) – hydrophilic acrylic.
Problem
Opacification of IOLs may occur following intracameral use of alteplase (recombinant tissue plasminogen activator, r-tPA).
The MHRA has been notified of 5 reports of the opacification of hydrophilic acrylic IOLs from 1 UK hospital. Opacification was noted between 5 months and seven years after alteplase treatment.
A study carried out by the hospital concluded that IOL opacification may be caused by intracameral use of alteplase to treat fibrinous membranes after cataract surgery.
Alteplase is a drug indicated for use in acute stroke, myocardial infarction, and pulmonary embolism. It is not licensed for intracameral use.
This could potentially be a problem with all hydrophilic acrylic IOLs. No manufacturing fault was found with the IOLs in this study.
Details of the study were presented as a poster at UKISCRS, 2009 (United Kingdom and Ireland Society of Cataract and Refractive Surgeons). The poster is attached in the appendix to this alert.
Action
- Ensure that all relevant staff are made aware of this issue.
- Report all IOL opacification incidents to the MHRA.
Distribution
This MDA has been distributed to:
- NHS trusts in England (Chief Executives)
- Care Quality Commission (CQC) (Headquarters)
- HSC trusts in Northern Ireland (Chief Executives)
- NHS boards in Scotland (Chief Executives)
- NHS boards and trusts in Wales (Chief Executives)
Onward distribution
Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:
Trusts to:
CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:
- Ophthalmic nurses
- Ophthalmologists
- Ophthalmic pharmacies
- Ophthalmology departments
- Eye units
- Ophthalmology, directors of
Care Quality Commission (CQC) (England only) to:
The MHRA considers this information to be important to:
- Hospitals in the independent sector
- Independent treatment centres
Feedback
If you have any comments or feedback on this Medical Device Alert, please email us at: [email protected]
Appendix
(386Kb)
England
If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/008 or 2009/010/005/081/020.
Technical aspects
Ian Smith or Michelle Kelly
Medicines and Healthcare products Regulatory Agency
Market Towers
1 Nine Elms Lane
London
SW8 5NQ
Tel: 020 7084 3306 or 3145
Fax: 020 7084 3106
Email: [email protected] or [email protected]
Clinical aspects
Dr Christopher Brittain
Medicines and Healthcare products Regulatory Agency
Market Towers
1 Nine Elms Lane
London
SW8 5NQ
Tel: 020 7084 3126
Fax: 020 7084 3111
Email: [email protected]
How to report adverse incidents
Please report via our website: Reporting adverse incidents involving medical devices.
Further information about CAS can be found on the Central Alerting System website .
Northern Ireland
Alerts in Northern Ireland will continue to be distributed via the NI SABS system.
Enquiries and adverse incident reports in Northern Ireland should be addressed to:
Northern Ireland Adverse Incident Centre (NIAIC)
Health Estates
Estate Policy Directorate
Stoney Road
Dundonald
Belfast
BT16 1US
Tel: 02890 523 704
Fax: 02890 523 900
Email: [email protected]
Northern Ireland Adverse Incident Centre (NIAIC)
How to report adverse incidents in Northern Ireland
Please report directly to NIAIC, further information can be found on the NIAIC website .
Further information about SABS can be found on the SABS website .
Scotland
Enquiries and adverse incident reports in Scotland should be addressed to:
Incident Reporting and Investigation Centre
Health Facilities Scotland
NHS National Services Scotland
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB
Tel: 0131 275 7575
Fax: 0131 314 0722
Email: [email protected]
Health Facilities Scotland - Incident Reporting and Investigation Centre
Wales
Enquiries in Wales should be addressed to:
Dr Sara Hayes
Senior Medical Officer
Medical Device Alerts
Welsh Assembly Government
Cathays Park
Cardiff
CF10 3NQ
Tel: 029 2082 3922
Email: [email protected]
Download documents